CLIN Clinigen Group Plc

TIDMCLIN

RNS Number : 1068J

Clinigen Group plc

30 November 2018

30 November 2018

Issue of Equity

Clinigen Group plc (AIM: CLIN, the "Group") announces that it has made an application for the admission to trading on AIM of 241,594 ordinary shares of 0.1 pence each in the Group (the "New Ordinary Shares"). These New Ordinary Shares have been issued to satisfy share options vesting under The Clinigen Group Long Term Incentive Plan and rank pari passu with the existing shares of the Group. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 5 December 2018.

At admission the issued share capital of the Group will consist of 132,433,092 ordinary shares, with no shares held in treasury. The total number of voting rights in the Group will therefore be 132,433,092. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interests in, the Group under the Disclosure Guidance and Transparency Rules.

-Ends-

Contact details

 
 Clinigen Group plc                             Tel: +44 (0) 1283 495010 
 Shaun Chilton, Group Chief Executive 
  Officer 
 Martin Abell, Group Chief Financial 
  Officer 
 Matt Parrish, Head of Investor Relations 
 
 Numis Securities Limited                       Tel: +44 (0) 20 7260 
                                                 1000 
 Michael Meade / Freddie Barnfield (Nominated 
  Adviser) 
  James Black / Tom Ballard (Corporate 
  Broking) 
 
 RBC Capital Markets - Joint Broker             Tel: +44 (0) 20 7653 
                                                 4000 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners                            Tel: +44 (0) 20 7457 
                                                 2020 
 Melanie Toyne-Sewell / Alex Shaw / 
  Deborah Bell                                  Email: clinigen@instinctif.com 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

IOEFDEFLSFASEIF

(END) Dow Jones Newswires

November 30, 2018 09:55 ET (14:55 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2024 to Apr 2024

Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2023 to Apr 2024